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To determine links between human rhinoviruses (HRV) 
and asthma, we used data from a case–control study, March 
2003–February 2004, among children with asthma. Molecu-
lar characterization identiﬁ  ed several likely new HRVs and 
showed that association with asthma exacerbations was 
largely driven by HRV-A and a phylogenetically distinct 
clade of 8 strains, genogroup C.
H
uman rhinovirus (HRV) infection triggers asthma ex-
acerbation (1), but there are no data on links between 
speciﬁ   c HRVs and asthma. Molecular sequence–based 
methods enabled recent identiﬁ   cation of several novel 
HRVs (2–9) and have made it practical to look for geno-
group and genotype-speciﬁ  c correlations with disease. In a 
previous study, we found a signiﬁ  cantly higher prevalence 
of HRVs in children with asthma exacerbations than in 
children with well-controlled asthma (10). In this study, we 
used molecular characterization methods to examine HRVs 
from these patients with asthma.
The Study
The case–control study was conducted in metropoli-
tan Atlanta, Georgia, USA, during March 2003–February 
2004, among children with asthma who were >2 years of 
age (10). Case-patients were deﬁ  ned as patients with asthma 
exacerbation; controls were deﬁ  ned as patients with stable 
asthma. Information on symptoms of acute viral respiratory 
illness was also collected. The deﬁ  nitions, epidemiologic 
and laboratory methods, and clinical description of patients 
are available from Table 1 and the previously published 
report (10).
HRVs were detected in nasopharyngeal swab speci-
mens by seminested reverse transcription–PCR (RT-PCR) 
targeting the 5′-noncoding region (NCR) (10). For further 
genetic characterization, HRV-positive samples were ex-
tracted from a previously unopened aliquot and ampliﬁ  ed 
by using a nested RT-PCR that targeted the virus capsid 
protein 1 (VP1) gene at positions 2432–2781, based on 
HRV 1B (GenBank accession no. D00239) for species A 
and positions 2531–2799, based on HRV 14 (GenBank 
accession no. NC_001490) for species B. We used Se-
quencher 3.1.1 software (Gene Codes, Ann Arbor, MI, 
USA) for sequence assembly and editing. Nucleotide and 
predicted amino acid sequences were aligned with previ-
ously published HRV VP1 sequences (GenBank acces-
sion nos. AY355180–AY3552831, EF186077, EF077279, 
EF077280, EF582385–EF582387) by using ClustalW as 
implemented in BioEdit (version 7.0.5) (www.mbio.ncsu.
edu/BioEdit/bioedit.html).
Phylogenetic trees were constructed by using the 
neighbor-joining algorithm implemented in PAUP* ver-
sion 4.0.d10 (11). Partial VP1 sequences for the novel 
HRV strains were submitted to GenBank (accession nos. 
EU312093–EU312101).
As reported previously (10), HRVs were detected by 
a 5′-noncoding region seminested RT-PCR in 53 (37%) of 
142 children with asthma, including 39 (60%) of 65 case-
patients and 14 (18%) of 77 controls. Of these, the HRVs 
from 29 (55%) (24 [62%] of the 39 HRV-positive case-pa-
tients and 5 [36%] of the 14 HRV-positive controls) were 
subsequently genotyped. VP1 sequences from the remaining 
24 HRV-positive specimens could not be obtained because 
of low amplicon yield (Table 2). Specimens from patients 
with symptoms of acute viral respiratory infection (Table 
1) were more likely than those from patients without viral 
symptoms to yield sufﬁ  cient VP1 amplicon for genotyping 
(percent genotyped 85% and 36%, respectively; odds ratio 
[OR] 9.1; 95% conﬁ  dence interval [CI] 2.1–50.0; p<0.05).
Of the 29 HRVs successfully genotyped, species A ac-
counted for 18 (62%) strains, species B accounted for 3 
(10%), whereas 8 (28%) strains formed a phylogenetically 
distinct clade, which we provisionally named “genogroup 
C” (Table 2, Figure). Of the 18 HRV-A strains, 17 showed 
close genetic relatedness (80.7%–93.8% nucleotide and 
89.6%–98.8% predicted amino acid sequence identity) to 
HRV prototype strains. One HRV-A strain (GA23584) 
was highly divergent from the closest prototype, HRV80 
(73.2% nucleotide and 73.0% amino acid sequence iden-
tity), which suggests that it could represent a distinct previ-
ously undescribed HRV. The 3 HRV-B strains were closely 
related to prototype strains (84.0%–88.6% nucleotide and 
89.7%–93.4% predicted amino acid sequence identity).
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Table 1. Criteria and definitions used in the study of children with asthma, March 2003–February 2004 (10) 
Category Criteria 
Current persistent asthma:   
  In children 2–5 y of age   All of the following:  
  1. Physician diagnosis of asthma 
 2.  >2 previous episodes of cough, wheeze, and/or respiratory distress 
  3. Current treatment with asthma medications 
  4. Parent or sibling with current or past diagnosis of asthma or allergy, and/or current or past  
    evidence of atopy (defined by seasonal rhinitis, eczema, or food hypersensitivity) 
  In children 6–17 y of age  All of the following: 
  1. Physician diagnosis of asthma 
  2. Symptoms of asthma in the past 12 mo 
  3. Current treatment with asthma medications  
Case (asthma exacerbation)  Current persistent asthma, hospital admission or clinic visit for asthma exacerbation, and all of the 
following:  
  1. Signs and symptoms of airflow obstruction (i.e., cough, wheeze, shortness of breath, chest  
    tightness) within past 48 h  
  2. Increased asthma symptoms resulting in hospital admission or clinic visit 
  3. Repeated use of short-acting ȕ-agonists within past 48 h 
  4. Increased dose or addition of a new asthma controller therapy within past wk 
Control (well-controlled asthma)  Current persistent asthma, routine clinic visit for asthma, and all of the following:  
  1. No systemic steroid therapy in past 4 wk 
  2. No increase in dose and no new controller medications in past wk 
  3. No change in the frequency of use of short-acting rescue medications in past wk 
  4. No increase in asthma symptom frequency in past wk 
Acute respiratory viral illness  >2 of the following: fever, stuffy/runny nose, headache, muscle aches, and pain or redness of 
eye(s) at the time of clinic visit or hospital admission 
Table 2. Human rhinoviruses identified in 53 pediatric patients with asthma, March 2003–February 2004, Atlanta, Georgia, USA* 
No. among HRV+ case-patients, n = 39 
 HRVs 
Receptor-
binding group 
No. among all HRV+ 
patients, n = 53 
Virus symptoms, 
n = 20 
No virus symptoms, 
n = 19 
No. among HRV+ 
controls, n = 14 
Total no. genotyped†  29 17 7 5
Species A  18 12 3 3
 HRV12  Major 1 1 0 0
 HRV30  Minor 2 2 0 0
 HRV36  Major 1 0 1 0
 HRV39  Major 1 0 0 1
 HRV43  Major 1 1 0 0
 HRV44  Minor 2 1 0 1
 HRV46  Major 1 1 0 0
 HRV49  Minor 2 1 1 0
 HRV53  Major 1 0 1 0
 HRV54  Major 1 1 0 0
 HRV61  Major 1 1 0 0
 HRV65  Major 1 1 0 0
 HRV66  Major 1 0 0 1
 HRV68  Major 1 1 0 0
 GA23584‡  Unknown  1 1 0 0
Species B  3 1 0 2
 HRV48  Major 1 0 0 1
 HRV99  Major 2 1 0 1
Genogroup C§  Unknown  8 4 4 0
Not genotyped  Unknown  24 3 12 9
*HRV, human rhinovirus; case-patients, asthma patients with exacerbations; controls, asthma patients without exacerbation. 
†HRV genotype based on partial virus capsid protein (VP1) gene sequence. Serotype designation based on >90% VP1 amino acid sequence identity with 
respective prototype strains. 
‡Strain GA23584 showed 73.0% amino acid sequence identity with HRV80. 
§Genogroup C HRVs form a clade phylogenetically distict from species A and B HRVs. Novel Human Rhinoviruses and Asthma
within the same genogroup ranged from 68.4% to 74.6% 
for nucleotide and from 68.5% to 85.5% for amino acid se-
quences. These novel viruses were related to other recently 
described HRVs: HRV–QPM detected in specimens from 
Australia (4), C024–C026 detected in specimens from Hong 
Kong (6), and NAT001 and NAT045 detected in specimens 
from California (8) (Figure). Their identity scores com-
pared with HRV–QPM were 66.0%–82.7% for nucleotide 
and 65.2%–86.9% for amino acid sequences. One of the 
strains (GA23592) was almost identical in partial VP1 se-
quence to C026 (Figure). The degree of genetic diversity 
among the genogroup C viruses far exceeded that between 
HRVs deﬁ  ned as distinct serotypes by classical serologic 
methods, which suggests that at least 7 of 8 of these viruses 
are antigenically distinct from each other rather than minor 
variants of the same serotype. The genogroup C HRV iden-
tity scores were substantially lower when compared with 
their closest matches from species A and B: 48.2%–51.1% 
for nucleotide and 38.5%–49.8% for amino acid sequenc-
es, and 35.9%–42.8% for nucleotide and 29.3%–35.8% for 
amino acid sequences, respectively.
Conclusions
In our study, the association of asthma exacerbations 
with HRV infection appeared to be largely driven by the 
novel genogroup C, which was found exclusively in case-
patients, and species A. The association was statistically 
signiﬁ  cant for species A (detected in 15 [23%] of 65 case-
patients vs. 3 [4%] of 77 controls; OR 7.4; 95% CI 1.9–
43.1; p<0.001) and for genogroup C (detected in 8 [12%] 
case-patients vs. 0 controls; OR undeﬁ  ned; p<0.010) but 
not for infrequently identiﬁ  ed species B (detected in 1 [2%] 
case-patient vs. 2 [3%] controls, p>0.05) or for HRVs that 
could not be genotyped (15 [23%] cases vs. 9 [12%] con-
trols; p>0.05). The distribution of HRVs between case-pa-
tients and controls still differed when the analysis was lim-
ited to the HRV-positive group (p = 0.05) or to genotyped 
HRVs only (p<0.05). The results of the only other study 
that reported novel HRVs in asthma patients (2 of which, 
NAT001 and NAT045, were related to genogroup C viruses 
in our study) are difﬁ  cult to interpret because that study of 
adults with “cold” symptoms showed an unexpected lack 
of association of HRVs with asthma exacerbation (8).
Patients infected with genogroup C HRVs had lower 
forced expiratory volumes during the ﬁ  rst second (FEV1) 
than did those infected with other HRVs (median 58.5% 
vs. 93%; p = 0.01), but the distribution of demographic 
and other clinical variables did not differ signiﬁ  cantly be-
tween the 2 groups. Lower FEV1 with genogroup C infec-
tion than with other HRVs suggests a potentially greater 
severity of asthma exacerbation in patients infected with 
these HRVs. When one considers the great variation among 
HRV serotypes in levels of sensitivity to candidate anti-
viral compounds (12,13), genogroup-related differences in 
associated disease patterns have implications for clinical 
management of HRV infections in asthma patients and for 
development of antiviral drugs against HRVs. Preliminary 
data suggest that HRV-QPM and related HRV-C strains 
from Hong Kong share certain VP1 sequence character-
istics with HRVs that are resistant to a candidate antipi-
cornavirus drug, pleconaril (4,6,13). These data raise the 
possibility that these novel HRVs might also be resistant to 
this compound.
The HRV-positive specimens from which VP1 gene 
sequences could not be obtained derived predominantly 
from patients without symptoms of acute respiratory viral 
illness. The absence of symptoms in HRV-infected persons 
likely reﬂ  ects subclinical, asymptomatic infection, which 
is common for HRVs (14), or HRV persistence after a re-
cently resolved infection (15), both of which are likely as-
sociated with lower viral loads (as opposed to acute symp-
tomatic infections), thus leading to lower detection rates in 
a VP1 assay that uses highly degenerate primers.
In conclusion, we found a striking genetic diversity of 
HRVs among children with asthma and conﬁ  rmed the ex-
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Figure. Phylogenetic tree of partial virus capsid protein 1 (VP1) 
amino acid sequences of human rhinoviruses (HRVs) identiﬁ  ed in 
29 HRV-positive pediatric asthma patients, March 2003–February 
2004, Atlanta, Georgia, USA (designated *), previously published 
sequences of strains QPM (GenBank accession no. EF186077), 
C024-C026 (accession nos. EF582385–EF582387), and NAT001 
and NAT045 (accession nos. EF077279–EF077280). HRV 
prototype strains designated 1A, 1B, 2-100. Human enterovirus 
(HEV) 68/HRV87 (designated 68/87) is included as outgroup.  Tree 
construction and bootstrap values determined with PAUP* (11).istence and wide geographic distribution (USA, Australia, 
Hong Kong) of HRVs distinct from both previously recog-
nized HRV species, A and B. Our ﬁ  nding supports the role 
of the novel HRVs as human pathogens. Additional studies 
are needed to further explore clinical and public health im-
plications of these ﬁ  ndings.
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